title: AFP-producing adenocarcinoma of the esophagogastric junction: report of a case with atypical immunohistochemical findings responding to palliative chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT regime).
abstract: AFP-producing adenocarcinoma of the esophagus and esophagogastric junction are rare tumor diseases. These tumors show an aggressive behavior characterized by early occurrence of liver metastases and mimic hepatocellular carcinoma (HCC). A general recommendation for palliative therapy is not established for these special tumors.Here we report about a 61-year-old man with multiple liver metastases and high serum alpha-fetoprotein (AFP) level. First, HCC was suspected, but further evaluation showed an AFP-producing adenocarcinoma of the esophagogastric junction with unusual findings on further immunohistochemical analysis. Palliative chemotherapy with FLOT (5-fluorouracil, leucovorin, oxaliplatin, and docetaxel) regime showed a 9 month duration of partial response.
authors.affiliation: Department of Internal Medicine I, Medical University Hospital, Tübingen, Germany.
authors.forename: U
authors.initials: U
authors.lastname: Häussler
authors.affiliation: Department of Internal Medicine I, Medical University Hospital, Tübingen, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Bitzer
authors.affiliation: Institute of Pathology, Medical University Hospital, Tübingen, Germany.
authors.forename: H
authors.initials: H
authors.lastname: Bösmüller
authors.affiliation: Department for Diagnostic and Interventional Radiology, Medical University Hospital, Tübingen, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Clasen
authors.affiliation: Department of Internal Medicine I, Medical University Hospital, Tübingen, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Götz
authors.affiliation: Department of Internal Medicine I, Medical University Hospital, Tübingen, Germany.
authors.forename: N P
authors.initials: NP
authors.lastname: Malek
authors.affiliation: Department of Internal Medicine I, Medical University Hospital, Tübingen, Germany.
authors.forename: R R
authors.initials: RR
authors.lastname: Plentz
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D000077143:Docetaxel; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*; D004943:Esophagogastric Junction / Q000473:pathology*; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D010166:Palliative Care / Q000379:methods*; D043823:Taxoids / Q000008:administration & dosage; D016896:Treatment Outcome; D000509:alpha-Fetoproteins / Q000378:metabolism
chemical_list: C097353:AFP protein, human; D009944:Organoplatinum Compounds; D043823:Taxoids; D000509:alpha-Fetoproteins; D000077150:Oxaliplatin; D000077143:Docetaxel; D002955:Leucovorin; D005472:Fluorouracil